ES2076521T3 - Procedimiento para la disociacion enzimatica de proteinas recombinantes mediando utilizacion de proteasa de iga. - Google Patents

Procedimiento para la disociacion enzimatica de proteinas recombinantes mediando utilizacion de proteasa de iga.

Info

Publication number
ES2076521T3
ES2076521T3 ES91902956T ES91902956T ES2076521T3 ES 2076521 T3 ES2076521 T3 ES 2076521T3 ES 91902956 T ES91902956 T ES 91902956T ES 91902956 T ES91902956 T ES 91902956T ES 2076521 T3 ES2076521 T3 ES 2076521T3
Authority
ES
Spain
Prior art keywords
procedure
enzymatic dissociation
recombinant proteins
zone
fused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902956T
Other languages
English (en)
Inventor
Thomas F Meyer
Johannes Pohlner
Gunter Schumacher
Carola Dony
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4015922A external-priority patent/DE4015922A1/de
Priority claimed from DE4039415A external-priority patent/DE4039415A1/de
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Application granted granted Critical
Publication of ES2076521T3 publication Critical patent/ES2076521T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PARA LA DISOCIACION ENZIMATICA DE PROTEINAS FUSIONADAS Y LA OBTENCION DE LAS PARTES DESEADAS DE ESTAS PROTEINAS FUSIONADAS, SE MODIFICA (1) CON METODOS DE INGENIERIA GENETICA UNA ZONA TRANSITORIA, EN LA QUE DOS PARTES DE LAS PROTEINAS FUSIONADAS ESTAN UNIDAS ENTRE SI, HASTA QUE SE PRODUZCA EN LA ZONA TRANSITORIA AL MENOS UNA ZONA DE RECONOCIMIENTO DE LA PROTEASA IGA CON LA SECUENCIA DEL AMINOACIDO Y-PRO-Ñ-X-PRO, EN LA CUAL X PUEDE SER UN AMINOACIDO CUALQUIERA E Y UNO O VARIOS AMINOACIDOS CUALQUIERA, (2) LA PROTEINA FUSIONADA RESULTANTE DEL PASO (1) ES DISOCIADA POR MEDIO DE LA PROTEASA IGA EN LA ZONA DE RECONOCIMIENTO SEÑALADA CON -Ñ-, Y (3) SE OBTIENEN DESPUES DE LA SEPARACION UNA O VARIAS PARTES DESEADAS DE LA PROTEINA FUSIONADA.
ES91902956T 1990-02-03 1991-02-01 Procedimiento para la disociacion enzimatica de proteinas recombinantes mediando utilizacion de proteasa de iga. Expired - Lifetime ES2076521T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4003149 1990-02-03
DE4015922A DE4015922A1 (de) 1990-05-17 1990-05-17 Verfahren zur enzymatischen prozessierung von proteinen unter verwendung von iga-proteasen (igase)
DE4015921 1990-05-17
DE4039415A DE4039415A1 (de) 1990-02-03 1990-12-10 Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest

Publications (1)

Publication Number Publication Date
ES2076521T3 true ES2076521T3 (es) 1995-11-01

Family

ID=27434868

Family Applications (2)

Application Number Title Priority Date Filing Date
ES91902956T Expired - Lifetime ES2076521T3 (es) 1990-02-03 1991-02-01 Procedimiento para la disociacion enzimatica de proteinas recombinantes mediando utilizacion de proteasa de iga.
ES93121015T Expired - Lifetime ES2177536T3 (es) 1990-02-03 1991-02-01 G-csf exento de metionina, procedente de procariotas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES93121015T Expired - Lifetime ES2177536T3 (es) 1990-02-03 1991-02-01 G-csf exento de metionina, procedente de procariotas.

Country Status (19)

Country Link
US (1) US5427927A (es)
EP (2) EP0513073B1 (es)
JP (2) JPH0789952B2 (es)
KR (1) KR960011919B1 (es)
AT (2) ATE124456T1 (es)
AU (1) AU638309B2 (es)
CA (1) CA2074943C (es)
CZ (1) CZ284774B6 (es)
DK (1) DK0513073T3 (es)
ES (2) ES2076521T3 (es)
FI (1) FI109810B (es)
HU (1) HU217103B (es)
IE (1) IE64938B1 (es)
IL (1) IL97119A0 (es)
LV (1) LV10309B (es)
NO (1) NO311142B1 (es)
NZ (1) NZ236819A (es)
PT (1) PT96658B (es)
WO (1) WO1991011520A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
DE4344350C2 (de) * 1993-12-23 1995-09-21 Max Planck Gesellschaft Bakterien zur Herstellung stabiler Fusionsproteine und Verfahren zu deren Nachweis
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
WO1996009395A2 (de) * 1994-09-21 1996-03-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Arzneimittel zur prophylaxe und behandlung von und diagnostika zur erkennung von autoimmunkrankheiten und viralen erkrankungen
AT404838B (de) * 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
GB9618960D0 (en) 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US6444202B1 (en) 1996-11-25 2002-09-03 Bundesrepublic Deutschland, Vertreten Durch Den Bundesminister Fur Gesundheit Processed polypeptides with IL-16 activity, processes for their production and their use
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US6818611B1 (en) * 1998-10-13 2004-11-16 University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
KR100356140B1 (ko) * 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
US7668658B2 (en) * 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
AU2003298733B2 (en) * 2002-11-27 2009-06-18 Agena Bioscience, Inc. Fragmentation-based methods and systems for sequence variation detection and discovery
EP1618135B1 (en) * 2003-04-23 2013-06-26 F.Hoffmann-La Roche Ag Cleavage of fusion proteins using granzyme b protease
EP1618216A2 (en) * 2003-04-25 2006-01-25 Sequenom, Inc. Fragmentation-based methods and systems for de novo sequencing
WO2005024068A2 (en) * 2003-09-05 2005-03-17 Sequenom, Inc. Allele-specific sequence variation analysis
CN1910293B (zh) 2003-10-23 2011-04-13 伊洛默格生物科学公司 检测与抗病毒感染性有关的基因oas1中的突变的方法
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
SI21639A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
CA2561381C (en) * 2004-03-26 2015-05-12 Sequenom, Inc. Base specific cleavage of methylation-specific amplification products in combination with mass analysis
US7608394B2 (en) 2004-03-26 2009-10-27 Sequenom, Inc. Methods and compositions for phenotype identification based on nucleic acid methylation
JP2008512129A (ja) * 2004-09-10 2008-04-24 セクエノム，インコーポレイティド 核酸の広範囲配列分析法
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
JP4958975B2 (ja) * 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
US20090006002A1 (en) * 2007-04-13 2009-01-01 Sequenom, Inc. Comparative sequence analysis processes and systems
DE102007040932A1 (de) 2007-08-27 2009-03-05 Biogenerix Ag Flüssigformulierung von G-CSF
MX2010002348A (es) 2007-08-27 2010-07-30 Biogenerix Ag Formulacion liquida de g-csf.
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用
US20110045510A1 (en) * 2008-04-03 2011-02-24 Kurt Lang Pegylated insulin-like-growth-factor assay
US8053222B2 (en) * 2009-02-12 2011-11-08 Academia Sinica, Taiwan Protein expression system involving mutated severe respiratory syndrome-associated coronavirus 3C-like protease
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
PT2525787T (pt) 2010-01-19 2017-12-18 Hanmi Science Co Ltd Formulações líquidas para conjugado de g-csf de longa ação
RU2013111677A (ru) * 2010-08-30 2014-10-10 Ф. Хоффманн-Ля Рош Аг Конструкция для экспрессии у прокариот
EP3004369A1 (en) * 2013-05-24 2016-04-13 Novo Nordisk A/S Fusion protease
RU2711322C1 (ru) * 2013-12-20 2020-01-16 Ф. Хоффманн-Ля Рош Аг Улучшенные способы получения рекомбинантного полипептида
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
US10446928B2 (en) 2017-06-09 2019-10-15 Mitsubishi Electric Corporation Phased array antenna
WO2025183146A1 (ja) * 2024-02-29 2025-09-04 積水メディカル株式会社 免疫学的測定方法、免疫学的測定用試薬、免疫学的測定用検体前処理液、免疫学的測定用試薬キット、及び非特異反応抑制剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL60184A (en) * 1979-05-31 1984-05-31 Schering Ag Process for the specific cleavage of protein sequences from proteins
ATE65798T1 (de) * 1985-02-08 1991-08-15 Chugai Pharmaceutical Co Ltd Menschlicher granuloxcyt-koloniestimulierungsfaktor.
JPS62129298A (ja) * 1985-12-02 1987-06-11 Chugai Pharmaceut Co Ltd 新規ポリペプチド
US5087564A (en) * 1985-06-20 1992-02-11 Monsanto Company Release of recombinant peptides from polypeptides using V8 endopeptidase
DE3681551D1 (de) * 1985-09-30 1991-10-24 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
FR2594846B1 (fr) * 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
US4828988A (en) * 1986-05-15 1989-05-09 Smith Kline - Rit Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine
DE3622221A1 (de) * 1986-07-02 1988-01-14 Max Planck Gesellschaft Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
AU7675487A (en) * 1986-08-11 1988-05-19 Cetus Corporation Expression of granulocyte colony-stimulating factor
IT1223577B (it) * 1987-12-22 1990-09-19 Eniricerche Spa Procedimento migliorato per la preparazione dell'ormone della crescita umano naturale in forma pura
EP0344796B1 (en) * 1988-06-03 1994-09-21 Chugai Seiyaku Kabushiki Kaisha Crystalline human granulocyte colony stimulating factor and process for preparing the same
PT92479A (pt) * 1988-12-01 1990-06-29 Univ North Carolina Processo de preparacao de genes recombinantes e suas proteinas de codificacao
US5055555A (en) * 1989-01-05 1991-10-08 Helmut Sassenfeld Purification of G-CSF
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3

Also Published As

Publication number Publication date
ATE219518T1 (de) 2002-07-15
JP2766621B2 (ja) 1998-06-18
PT96658B (pt) 1998-09-30
EP0513073B1 (de) 1995-06-28
NO923010L (no) 1992-09-14
WO1991011520A1 (de) 1991-08-08
IE64938B1 (en) 1995-09-20
AU638309B2 (en) 1993-06-24
PT96658A (pt) 1991-10-31
CZ284774B6 (cs) 1999-02-17
LV10309B (en) 1995-12-20
JPH07278195A (ja) 1995-10-24
FI923463L (fi) 1992-07-31
LV10309A (lv) 1994-10-20
DK0513073T3 (da) 1995-10-30
ES2177536T3 (es) 2002-12-16
KR960011919B1 (ko) 1996-09-04
NO311142B1 (no) 2001-10-15
EP0513073A1 (de) 1992-11-19
CS9100241A2 (en) 1991-08-13
HUT63195A (en) 1993-07-28
IL97119A0 (en) 1992-03-29
FI923463A0 (fi) 1992-07-31
EP0602688A1 (en) 1994-06-22
ATE124456T1 (de) 1995-07-15
IE910358A1 (en) 1991-08-14
JPH05501360A (ja) 1993-03-18
CA2074943C (en) 1999-12-07
HU9202511D0 (en) 1992-10-28
US5427927A (en) 1995-06-27
NO923010D0 (no) 1992-07-30
FI109810B (fi) 2002-10-15
EP0602688B1 (de) 2002-06-19
JPH0789952B2 (ja) 1995-10-04
NZ236819A (en) 1993-07-27
AU7149691A (en) 1991-08-21
HU217103B (hu) 1999-11-29
CA2074943A1 (en) 1991-08-04

Similar Documents

Publication Publication Date Title
ES2076521T3 (es) Procedimiento para la disociacion enzimatica de proteinas recombinantes mediando utilizacion de proteasa de iga.
DK1218751T3 (da) Cöliakidiagnose under anvendelse af et gliadinepitop
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
DK0894126T3 (da) Alkalisk phosphatase-deficient trådformet svamp
DK0542863T3 (da) Ekspression af rekombinante polypeptider med forbedret oprensning
DK3688D0 (da) Pankreatisk sekretorisk trypsininhibitor og varianter deraf fremstillet af en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert samt farmaceutisk anvendelse deraf
DE69131929D1 (de) Methoden zur trans-destabilisierung von spezifischen proteinen in vivo
ES2109217T3 (es) Determinante peptidico asociado con la inmunidad.
ATE471986T1 (de) Verbesserung der homogenität und sekretion von rekombinanten proteinen in säugetiersystemen
DK0641861T3 (da) Fremgangsmåde til fremstilling af hydrofobe polypeptider, proteiner eller peptider
DE60120374D1 (de) Methoden zur reinigung von stark anionischen proteinen
DE3854550D1 (de) HIV-Peptide und Methoden für den Nachweis von HIV.
NO930428D0 (no) Proteinstrukturen til plantetoksingelonin
DK450187D0 (da) Fremgangsmaade til fremstilling af proteiner
DE69331742D1 (de) Neuartige protease
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 513073

Country of ref document: ES